Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatoblastoma | 7 | 2024 | 58 | 1.550 |
Why?
|
| RNA, Long Noncoding | 6 | 2025 | 57 | 1.470 |
Why?
|
| Liver Neoplasms | 9 | 2024 | 231 | 1.450 |
Why?
|
| Gene Expression Regulation, Neoplastic | 14 | 2025 | 732 | 1.120 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2023 | 152 | 0.810 |
Why?
|
| Gene Expression Profiling | 13 | 2023 | 533 | 0.780 |
Why?
|
| Transcriptome | 3 | 2023 | 232 | 0.720 |
Why?
|
| MicroRNAs | 11 | 2025 | 228 | 0.580 |
Why?
|
| Gene Regulatory Networks | 6 | 2018 | 108 | 0.500 |
Why?
|
| Neoplasms | 6 | 2024 | 720 | 0.440 |
Why?
|
| RNA, Messenger | 8 | 2025 | 719 | 0.400 |
Why?
|
| Humans | 65 | 2025 | 26278 | 0.390 |
Why?
|
| Sequence Analysis, RNA | 5 | 2023 | 118 | 0.350 |
Why?
|
| Cell Line, Tumor | 18 | 2025 | 1225 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2021 | 193 | 0.270 |
Why?
|
| Mutation | 8 | 2023 | 1418 | 0.260 |
Why?
|
| Ribonuclease III | 2 | 2025 | 32 | 0.230 |
Why?
|
| DEAD-box RNA Helicases | 2 | 2025 | 45 | 0.230 |
Why?
|
| Glioblastoma | 3 | 2018 | 127 | 0.230 |
Why?
|
| Separase | 2 | 2014 | 14 | 0.210 |
Why?
|
| Mice | 24 | 2025 | 4912 | 0.210 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 221 | 0.200 |
Why?
|
| Single-Cell Analysis | 2 | 2024 | 79 | 0.190 |
Why?
|
| Animals | 33 | 2025 | 8267 | 0.190 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2022 | 33 | 0.190 |
Why?
|
| Cognitive Dysfunction | 1 | 2022 | 20 | 0.180 |
Why?
|
| Child | 7 | 2024 | 8226 | 0.180 |
Why?
|
| Down Syndrome | 1 | 2022 | 37 | 0.180 |
Why?
|
| Chromosome Aberrations | 1 | 2022 | 173 | 0.180 |
Why?
|
| Oxadiazoles | 1 | 2021 | 12 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2024 | 112 | 0.170 |
Why?
|
| Piperazines | 1 | 2021 | 43 | 0.170 |
Why?
|
| Neoplasm Transplantation | 2 | 2017 | 168 | 0.170 |
Why?
|
| Amish | 1 | 2020 | 1 | 0.160 |
Why?
|
| Cell Cycle Proteins | 1 | 2021 | 201 | 0.160 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 225 | 0.150 |
Why?
|
| Prognosis | 7 | 2024 | 1190 | 0.150 |
Why?
|
| Fetal Hemoglobin | 1 | 2018 | 4 | 0.150 |
Why?
|
| Young Adult | 3 | 2024 | 2355 | 0.150 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2018 | 8 | 0.150 |
Why?
|
| Erythroid Cells | 1 | 2018 | 7 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2021 | 236 | 0.140 |
Why?
|
| RNA, Neoplasm | 2 | 2018 | 48 | 0.140 |
Why?
|
| Receptor, EphA2 | 1 | 2018 | 7 | 0.140 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2018 | 13 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 15 | 0.140 |
Why?
|
| Antigenic Variation | 1 | 2018 | 17 | 0.140 |
Why?
|
| Oncogenes | 3 | 2018 | 56 | 0.140 |
Why?
|
| Genome, Human | 3 | 2021 | 311 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 353 | 0.140 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 75 | 0.140 |
Why?
|
| Genomics | 3 | 2018 | 388 | 0.140 |
Why?
|
| Metformin | 1 | 2018 | 38 | 0.140 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2017 | 21 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 66 | 0.140 |
Why?
|
| Atazanavir Sulfate | 1 | 2017 | 5 | 0.140 |
Why?
|
| Models, Biological | 3 | 2018 | 363 | 0.140 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 78 | 0.140 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 26 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 167 | 0.130 |
Why?
|
| Disease Models, Animal | 9 | 2025 | 1086 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2023 | 136 | 0.130 |
Why?
|
| Quinazolines | 1 | 2017 | 73 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2018 | 193 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2025 | 434 | 0.130 |
Why?
|
| Cell Line | 8 | 2021 | 694 | 0.130 |
Why?
|
| HIV Infections | 2 | 2022 | 500 | 0.130 |
Why?
|
| Algorithms | 11 | 2015 | 318 | 0.120 |
Why?
|
| DNA Copy Number Variations | 2 | 2020 | 319 | 0.120 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 235 | 0.120 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 212 | 0.120 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2015 | 17 | 0.120 |
Why?
|
| Gene Expression Regulation | 5 | 2019 | 570 | 0.120 |
Why?
|
| Pluripotent Stem Cells | 1 | 2015 | 19 | 0.110 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 23 | 0.110 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2023 | 35 | 0.110 |
Why?
|
| T-Lymphocytes | 6 | 2024 | 526 | 0.110 |
Why?
|
| Kidney Neoplasms | 1 | 2015 | 99 | 0.110 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 1005 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2015 | 238 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 273 | 0.110 |
Why?
|
| RNA Interference | 2 | 2014 | 156 | 0.110 |
Why?
|
| Cell Nucleus | 1 | 2014 | 129 | 0.110 |
Why?
|
| Computational Biology | 9 | 2024 | 191 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 208 | 0.100 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2013 | 96 | 0.100 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 254 | 0.090 |
Why?
|
| Female | 19 | 2024 | 15228 | 0.090 |
Why?
|
| Transcription Factors | 10 | 2019 | 762 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 431 | 0.080 |
Why?
|
| Gene Knockdown Techniques | 2 | 2021 | 115 | 0.080 |
Why?
|
| Male | 21 | 2025 | 13636 | 0.070 |
Why?
|
| Hep G2 Cells | 2 | 2018 | 24 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 135 | 0.070 |
Why?
|
| Cell Differentiation | 4 | 2025 | 463 | 0.070 |
Why?
|
| Databases, Genetic | 3 | 2018 | 106 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2018 | 303 | 0.070 |
Why?
|
| Apoptosis | 5 | 2021 | 571 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2024 | 1127 | 0.070 |
Why?
|
| Heterografts | 2 | 2017 | 90 | 0.070 |
Why?
|
| Liver | 8 | 2021 | 402 | 0.060 |
Why?
|
| Signal Transduction | 7 | 2025 | 1372 | 0.060 |
Why?
|
| Child, Preschool | 7 | 2024 | 4935 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2015 | 443 | 0.050 |
Why?
|
| Estrogen Receptor alpha | 2 | 2014 | 194 | 0.050 |
Why?
|
| Oxycodone | 1 | 2022 | 4 | 0.050 |
Why?
|
| Rats, Transgenic | 3 | 2022 | 5 | 0.050 |
Why?
|
| Receptors, Cytokine | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2022 | 62 | 0.050 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2024 | 34 | 0.050 |
Why?
|
| HIV | 1 | 2022 | 31 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2022 | 68 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 95 | 0.050 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 49 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 2022 | 168 | 0.040 |
Why?
|
| Rats | 4 | 2024 | 777 | 0.040 |
Why?
|
| Genetics, Population | 1 | 2020 | 21 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2020 | 53 | 0.040 |
Why?
|
| Heterozygote | 1 | 2020 | 144 | 0.040 |
Why?
|
| DNA Mutational Analysis | 2 | 2020 | 173 | 0.040 |
Why?
|
| Pedigree | 2 | 2020 | 370 | 0.040 |
Why?
|
| gamma-Globins | 1 | 2018 | 2 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 40 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 43 | 0.040 |
Why?
|
| RNA Precursors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 35 | 0.040 |
Why?
|
| Protein Domains | 2 | 2023 | 82 | 0.040 |
Why?
|
| Transduction, Genetic | 1 | 2018 | 85 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2018 | 91 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2018 | 216 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2025 | 77 | 0.030 |
Why?
|
| Adult | 4 | 2024 | 5769 | 0.030 |
Why?
|
| Cytochromes | 1 | 2017 | 5 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2019 | 341 | 0.030 |
Why?
|
| Chimera | 1 | 2017 | 17 | 0.030 |
Why?
|
| Mice, Inbred Strains | 2 | 2017 | 80 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 297 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2017 | 30 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 197 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 86 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2018 | 134 | 0.030 |
Why?
|
| Base Sequence | 5 | 2018 | 806 | 0.030 |
Why?
|
| Gene Expression | 3 | 2019 | 404 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 366 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2018 | 791 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 115 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2015 | 8 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 566 | 0.030 |
Why?
|
| Immunoblotting | 2 | 2015 | 90 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 574 | 0.030 |
Why?
|
| Gene Duplication | 1 | 2015 | 90 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2018 | 350 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 446 | 0.030 |
Why?
|
| Cell Proliferation | 5 | 2019 | 858 | 0.030 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 50 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2014 | 98 | 0.030 |
Why?
|
| Binding Sites | 7 | 2014 | 331 | 0.030 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 434 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2013 | 30 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 6 | 2022 | 484 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 93 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 824 | 0.030 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2013 | 46 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2013 | 157 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 170 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 778 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2014 | 171 | 0.030 |
Why?
|
| Recurrence | 2 | 2023 | 354 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2013 | 346 | 0.020 |
Why?
|
| Survival Rate | 1 | 2014 | 489 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 608 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 1224 | 0.020 |
Why?
|
| Infant | 5 | 2024 | 4212 | 0.020 |
Why?
|